within Pharmacolibrary.Drugs.ATC.B;

model B05AA06
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.001,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B05AA06</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Gelatin agents, also known as plasma substitute solutions containing degraded gelatin, are used for plasma volume expansion in hypovolemia, such as during shock and massive blood loss. They act as colloidal solutions to maintain plasma oncotic pressure and are used where rapid expansion of plasma is required. These agents are still approved and used in some countries, though their use is decreasing due to concerns about anaphylactic reactions and kidney effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult individuals after intravenous infusion, as no direct publication with specific PK model and values was found.</p><h4>References</h4><ol><li><p>Son, J, et al., &amp; Koo, H (2019). Gelatin-chlorin e6 conjugate for in vivo photodynamic therapy. <i>Journal of nanobiotechnology</i> 17(1) 50–None. DOI:<a href=\"https://doi.org/10.1186/s12951-019-0475-1\">10.1186/s12951-019-0475-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30953510/\">https://pubmed.ncbi.nlm.nih.gov/30953510</a></p></li><li><p>Levêque, D, &amp; Jehl, F (1996). Clinical pharmacokinetics of vinorelbine. <i>Clinical pharmacokinetics</i> 31(3) 184–197. DOI:<a href=\"https://doi.org/10.2165/00003088-199631030-00003\">10.2165/00003088-199631030-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8877249/\">https://pubmed.ncbi.nlm.nih.gov/8877249</a></p></li><li><p>Winer, EP, et al., &amp; Spicer, DV (1995). Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. <i>Seminars in oncology</i> 22(2 Suppl 5) 72–79. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7740337/\">https://pubmed.ncbi.nlm.nih.gov/7740337</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B05AA06;
